Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)

Phase 3TerminatedNCT01656434

Organon and Co3,173 enrolled

Overview

The purpose of this study was to assess the contraceptive efficacy of a nomegestrol acetate + 17ß-estradiol (NOMAC-E2) combined oral contraceptive (COC) in healthy, sexually-active American women at risk for pregnancy. Vaginal bleeding patterns of women taking NOMAC-E2 were assessed and compared to those of women taking a norethisterone acetate + ethinyl estradiol (NETA-EE) COC. The safety of NOMAC-E2 was also assessed. Participants were randomized to receive either NOMAC-E2 or NETA-EE in a 3:1 ratio. As of Amendment 1 (which increased the sample size of the NOMAC-E2 group), the randomization ratio was adapted accordingly for participants randomized after the sample size increase.

This study was terminated early. The decision to terminate the study was based upon difficulties encountered with data collection (related to incomplete e-Diary entries) in concert with business considerations. The decision was not related to any new or unexpected safety or efficacy findings with NOMAC-E2. As a result of this early termination, none of the pre-specified efficacy endpoints were analyzed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

3,173

Conditions

Contraception

Interventions

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Sexually active woman, at risk for pregnancy and in need of contraception * Not planning to use other contraceptive methods (including barrier methods \[e.g., condoms\]) than the study drug, during the study * Willing to use a COC for 12 months (13 cycles) * Body mass index (BMI) of ≥18 and \<38 kg/m\^2 * Good physical and mental health * Willing to complete an electronic diary on a daily basis for the duration of the study Exclusion Criteria: * Current smoker and age of \>35 years * Presence or history of either venous thromboembolic diseases (deep vein thrombosis \[DVT\], pulmonary embolism) or arterial thromboembolic diseases (myocardial infarction, stroke) * History of migraine with focal neurological symptoms * Diabetes mellitus with vascular involvement * Less than two weeks of full remobilization from prolonged immobilization, major surgery, any surgery to the legs, or major trauma * Severe hypertension * Severe abnormal lipoproteins in the blood * Pancreatic dysfunction * Presence of history of severe liver disease or liver tumors * Known or suspected sex steroid-influenced malignancies (e.g., of the genital organs or the breasts) * Undiagnosed vaginal bleeding * Known or suspected pregnancy * Current or history of abuse of alcohol or drugs (e.g., laxatives) * Abnormal cervical smear at screening * Prior to start of treatment, spontaneous menstruation has not occurred following a delivery or abortion * Breastfeeding or has been breastfeeding within 2 months prior to start of treatment * Use of any investigational drugs and/or participation in any other clinical trial within 2 months prior to start of treatment * Use of any of the following medications prior to or during the study may prohibit inclusion: sex hormones (other than pre- and post-treatment non-injectable contraceptives), injectable hormonal contraception, phenytoin, barbiturates, primidone, bosentan, carbamazepine, topiramate, felbamate, rifampicin, ritonavir, nevirapine, efavirenz, griseofulvin, herbal remedies containing Hypericum perforatum (e.g., St. John's wort)

Outcomes

Primary Outcomes

Number of In-Treatment Pregnancies Per 100 Woman Years of Exposure (Pearl Index)

Primary Efficacy Outcome measure for this study was contraceptive efficacy, or the prevention of in-treatment pregnancy. The total incidence of in-treatment pregnancies was expressed as the Pearl Index, which is defined as the number of in-treatment pregnancies per 100 woman-years of exposure.

Time frame: Up to 1 year (13 cycles)

Secondary Outcomes

Percentage of Participants With an Occurrence of Breakthrough Bleeding/Spotting

Participants kept e-diaries to record their vaginal bleeding events. They were asked to record, on a daily basis, whether they experienced vaginal bleeding, which included BLEEDING or SPOTTING, at any time during a cycle other than normal menstruation while in the study. (This is also known as "breakthough" bleeding.) Vaginal bleeding that required \>=1 pad/tampon per day was classified as BLEEDING. Vaginal bleeding that did not require a pad/tampon per day was classified as SPOTTING.

Time frame: Up to 1 year (13 cycles)

Percentage of Participants With an Absence of Withdrawal Bleeding

Participants kept e-diaries to record vaginal bleeding events. They were asked to record, on a daily basis, whether vaginal bleeding was present. Absence of withdrawal bleeding was defined as no bleeding/spotting during the expected bleeding period.

Time frame: Up to 1 year (13 cycles)

Percentage of Participants Who Experienced At Least One Adverse Event

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.

Time frame: Up to 54 weeks

Number of Participants Who Experience at Least One Venous or Arterial Thrombotic/Thromboembolic Event

Time frame: Up to 54 weeks

Change From Baseline in Body Weight

Participants' body weights were measured in a consistent manner throughout the trial, using standardized equirpment. Last In-Treatment Measurement refers to a participant's end of trial visit, the timing of which differed among participants.

Time frame: Baseline and Week 52